Prevention of coronary heart disease in clinical practice: Recommendations of the second joint Task Force of European and other societies on coronary prevention

Atherosclerosis

Volumn 140, Issue 2, 1998, Pages 199-270

  Wood, David ^a   De Backer, Guy ^a   Faergeman, Ole ^a   Graham, Ian ^a   Mancia, Giuseppe ^a   Pyörälä, Kalevi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; DIET; EDITORIAL; EUROPE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION;

EID: 0031728287     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)90209-X     Document Type: Article

References (476)

1. Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur. Heart. J. 18:1997;1231-1248.
2. Marmot M.G., Shipley M.J., Rose G. Inequalities in death - specific explanations of a general pattern? Lancet. II:1984;1003-1006.
3. Marmot M.G., Kogevinas M., Elston M.A. Socioeconomic status and disease. WHO. Reg. Publ. Eur. Ser. 37:1991;113-146.
4. Jacobsen B.K., Thelle D.S. Risk factors for coronary heart disease and levels of education. The Tromso Heart Study. Am. J. Epidemiol. 127:1988;923.
5. Winkleby M.A., Fortmann S.P., Barett D.C. Social class disparaties in risk factors for disease. Eight-year prevalence patterns by level of education. Prev. Med. 19:1990;1-12.
6. Luepker R.V., Rosamond W.D., Murphy R. et al. Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart Survey. Circulation. 88(1):1993;2172-2179.
7. Wagenknecht L.E., Perkins L.L., Cutter G.R. et al. Cigarette smoking is strongly related to educational status. The CARDIA Study. Prev. Med. 19:1990;158-169.
8. Osler M. Social class and health behaviour in Danish adults: a longitudinal study. Public. Health. 107:1993;251-260.
9. Bolton-Smith C., Smith W.C.S., Woodward M., Tunstall-Pedoe H. Nutrient intakes of different social-class groups. Results from the Scottish Heart Health Study (SHHS). Br. J. Nutr. 65:1991;321-335.
10. Nourjah P., Wagener D.K., Eberhardt M., Orowitz A.M. Knowledge of risk factors and risk behaviours related to coronary heart diseases among blue and white collar males. J. Public. Health. Policy. 15(4):1994;443-459.
11. Sobal J. Obesity and socioeconomic status: a framework for examining relationships between physical and social variables. Med. Anthropol. 13:1991;231-247.
12. Burke G.L., Savage P.J., Manorio T.A. et al. Correlates of obesity in younger black and white women: The CARDIA Study. Am. J. Pub. Health. 82(12):1992;1621-1625.
13. Orth-Gomer K., Rosengren A., Wilhemsen L. Lack of social support and incidence of coronary heart disease in middle-age Swedish men. Psychosom. Med. 55:1993;37-43.
14. Bosma H., Marmot M.G., Hemingway H., Nicholson A., Brunner E.J., Stanfeld S. Low job control and risk of coronary heart disease in the Whitehall II (prospective cohort) study. Br. Med. J. 314:1997;558-565.
15. Theorell T., Tsutsumi A., Hallqvist J. et al. Decision latitude, job strain and myocardial infarction: a study of working men in Stockholm. Am. J. Public. Health. 88(3):1998;382-388.
16. Chesney A.M. Social support and heart disease in women. Implications for intervention. Orth-Gomer K., Chesney A.M., Wenger N.K. Women, stress and heart disease. 1998;165-184 Lawrence Arlbaum, Mahwah, NJ.
17. Lynch J.W., Kaplan G.A., Cohen R.D. et al. Do cardiovascular risk factors explain the relation between socio-economic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am. J. Epidemiol. 144(10):1996;934-942.
18. Marmot M.G., Bosma H., Hemingway H., Brunner E., Stansfeld S. Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet. 350:1997;235-239.
19. Wamala SP, Orth-Gomer K. Interfaces of human biology and social organization: challenges for future research. A National Report on Promoting Research on Inequality in Health in Sweden, 1998.
20. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31; Atherosclerosis 1994;110:121-61.
21. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31; Atherosclerosis 1994;110:121-61.
22. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevence ischemické choroby srdecní v klinické praxi. Cor. Vasa. 37:1995;K123-125.
23. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Cyprus. Med. J. 13:1995;3-12.
24. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prévention de la maladie coronarienne en pratique clinique. Coeur. Vaiss. 10:1995;1493-1535.
25. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Hellenic. J. Cardiol. 36:1995;228-238.
26. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Koronãrãs sirds slimibas profilakse kliniskã praksê. Eiropas Kardiologu biedrivas, Eiropas Aterosklerozes biedribas un Eiropas Hipertensijas biedribas kopêjãa darba grupas ietikumi. Latvias. Arsts. 10:1995;6-12.
27. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Hjerteforum. 2:1995;23-33.
28. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Material Metodologic-Prevenirea Cardiopatiei Ischemice in Practica Cliniã. Recomandãrile grupuliu de experti ai Societãtii Europene de Cardiologie, ai Societãtii Europene de Aterosclerozã si ai Societãtii Europene de Hipertensiune. Rev. Rom. Cardiol. 1:1995;25-29.
29. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevención de la enfermedad coronaria en la práctica clínica. Recomendaciones del Grupo de Trabajo de la Sociedad Europea de Cardiologia (ESC), Sociedad Europea de Aterosclerosis (EAS) y Sociedad Europea de Hipertensión (ESH). Rev. Esp. Cardiol. 48:1995;773-780.
30. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Koroner Kalp Hastahgindan Korunma ve Tedaviye Iliskin Ulusal Kilavuz. Türk. Kardiyol. Dern. Ars. 23:1995;213-224.
31. Kühn P. Die Herzrisikotabelle fass für den niedergelassene Arzt die wichtigsten Fakten der Herz-Kreislaufprävention zusammen. J. Austrian. Med. Assoc. 10:1996;28-33.
32. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prévention de la maladie coronarienne en pratique clinique: résumé pour les cliniciens. J. Cardiol. 8:1996;71-80.
33. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevencija koronarne bolesti srca u klinickoj praksi. Preporuke Radne skupine Europskoga kardioloskog drustva, Europskoga drustva za aterosklerozu I Europskoga drustva za hipertenziju. J. Croat. Med. Assoc. 10(108):1996;221-226.
34. European Society of Cardiologyn, European Atherosclerosis Societyn ja European Society of Hypertensionin Task Forcen suosituksen suomalainen sovellus. Suom. Lääkäril. 51:1996;783-802.
35. Östor E. A coronariabetegség prevenciója a klinikai gyakorlatban. Cardioscan. 2:1996;43-48.
36. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Ir. Coll. Phys. Surg. 25(4):1996;249-256.
37. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevenzione della malattia coronarica nella pratica clinica. Raccomandazioni della Task Force costituita da European Society of Cardiology, European Atherosclerosis Society e European Society of Hypertension. Cardiologia. 41(2):1996;149-182.
38. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevenirea Cardiopatiei Ischemice in Practica Clinica (Recomandarile grupului de experti al societãtilor Europene de Cardiologie, Ateroscleroza si Hipertensiune). Curier. Med. 2:1996;56-59.
39. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Zapobieganie chorobie wiencowej. Zalecenia Porozimienia zawartego przez Europejskie Towarzystwo Kardiologiczne, Europejskie Towarzystwo Badan nad Miazdzy-ca I Europejskie Towarzystwo Nadcisnieniowe. Zdrowe. Serce. 3:1996;4-20.
40. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Recomendações na Prevenção Primária e Secundária da Doença das Coronárias. Soc. Port. Cardiol. Ateroscler. Hipertens. 4:1996;7-40.
41. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Russ Med Soc Cardiol 1996;1-60.
42. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevencia ischemickej choroby srdca v klnickej praxi-suhrn pre klinikov. Odporúcania Komisie Európskej Kardiologickej Spolocnosti, Európskej Spolocnosti pre Aterosklerózu a Európskej spolocnosti pre Hypertenziu. Noninvas. Cardiool. 5(2):1996;A3-A9.
43. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Ukr. J. Cardiol. 5:1996;81-84.
44. Smith S.C., Blair S.N.m, Criqui M.H. et al. AHA medical/scientific statement. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
45. Fuster V., Pearson T.A. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. JACC. 27:1996;957-1047.
46. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through intervention to reduce events. Eur. Heart. J. 18:1997;1569-1592.
47. Bowker T.J., Clayton T.C., Ingham J. et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease - ASPIRE. Heart. 75:1996;334-342.
48. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
49. Sacks F.M., Pfeffer M.A., Moye L. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New. Engl. J. Med. 335:1996;1001-1009.
50. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am. J. Cardiol. 76:1995;474-479.
51. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New. Engl. J. Med. 333:1995;1301-1307.
52. Downs G.R., Clearfield M., Weiss S. et al. Primary prevention of acute coronary events with lovastatin in menand women with average cholesterol levels: results of AFCAPS/TEXCAPS (Air Force/Texas Coronary Atherosclerosis Study). J. Am. Med. Assoc. 279:1998;1615-1622.
53. Grundy S.M., Baladt G.J., Criqui M.H. et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. Circulation. 95:1997;1683-1685.
54. Grundy S.M., Balady G.J., Criqui M.H. et al. Guide to primary prevention of cardiovascular diseases. Circulation. 95:1997;2329-2331.
55. Pearson T., Rapaport E., Criqui M. et al. Optimal risk factor management in the patient after coronary revascularisation. A statement for healthcare professionals from an American Heart Association Writing Group. Circulation. 90:1994;3125-3133.
56. Prevention of Coronary Heart Disease. Report of a WHO Expert Committee. WHO technical report series 678. Geneva: World Health Organization, 1982.
57. Barker D.J.P. Fetal origins of coronary heart disease. Br. Med. J. 311:1995;171-174.
58. Cardiovascular disease risk factors: new areas for research. Report of a WHO Scientific Group. WHO technical report series 841. Geneva: World Health Organization, 1994.
59. Anderson K.M., Wilson P.W.F., Odell P.M., Kannel W.B. An updated coronary risk profile: A statement for health professionals. Circulation. 83:1991;356-362.
60. Ettinger W.H., Wahl P.W., Kuller L.H. et al. Lipoprotein lipids in old people. Results from Cardiovascular Health Study. Circulation. 86:1992;858-869.
61. Kornitzer M., De Backer G., Dramaix M. et al. Belgian Heart Disease Prevention Project: incidence and mortality results. Lancet. I:1983;1066-1070.
62. Hjermann I., Velve Byre K., Holme I., Leren P. Effects of diet and smoking intervention on the incidence of coronary heart disease. Lancet. II:1981;1303-1310.
63. European Collaborative Trial of Multifactorial Prevention of Coronary Heart Disease: final report of the 6-years results. Lancet. I:1986;869-872.
64. Multiple risk factor intervention trial. Risk factor changes and mortality results. J. Am. Med. Assoc. 248:1982;1465-1477.
65. Wilhemsen L., Berglund G., Elmfeldt D. et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur. Heart. J. 7:1986;279-288.
66. Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. Findings related to a priori hypotheses of the trial. J. Am. Med. Assoc. 263:1990;1795-1801.
67. De Backer G., Kornitzer M., Dramaix M., Kittel F., Thilly C., Graffar M., Vuylsteek K. The Belgian Heart Disease Prevention Project: 10-year mortality follow-up. Eur. Heart. J. 9:1988;238-242.
68. Rose G. WHO European collaborative trial of multifactorial prevention of coronary heart disease. Lancet. I:1987;685.
69. Clarke R., Frost C., Collins R. et al. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. Br. Med. J. 314:1997;112-117.
70. Diet, nutrition and prevention of chronic diseases. Report of a WHO Study Group. WHO technical report series 797. Geneva: World Health Organization, 1990.
71. Van Poppel G. Intake of trans fatty acids in Western Europe: the TRANSFAIR Study. Lancet. 351:1998;1099.
72. Katan M.B., Grundy S.M., Willett W.C. Beyond low fats. Clinical debate. New. Engl. J. Med. 337:1997;563-567.
73. Miettinen T.A., Naukkarinen V., Huttunen J., Mattila S., Kumlin T. Fatty acid composition of serum lipids predicts myocardial infarction. Br. Med. J. 285:1982;993-996.
74. Wood D.A., Riemersma R.A., Butler S. et al. Linoleic and eicosapentaenoic acids in adipose tissue and platelets and risk of coronary heart disease. Lancet. I:1987;177-183.
75. De Lorgeril M., Renaud S., Mamelle N. et al. Mediterranean α-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 343:1994;1454-1459.
76. Burr M.L., Fehily A.M., Gilbert J.F. et al. Effects of changes in fat, fish and fibre intakes on death and myocardial re-infarction: diet and re-infarction trial (DART). Lancet. II:1989;757-761.
77. De Deckere EAM, Korver O, Verschuren PM, Katan MB. Health aspects of fish and N-3 polyunsaturated fatty acids from plant and animal orign. Eur J Clin Nutr (in press).
78. Ness A., Powles J.W. Fruit and vegetables, and cardiovascular disease: a review. Int. J. Epidemiol. 26:1997;1-13.
79. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witzum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New. Engl. J. Med. 320:1989;915-924.
80. Stampfer M.J., Hennekens C.H., Manson J.E. et al. Vitamin E consumption and the risk of coronary disease in women. New. Engl. J. Med. 328:1993;1444-1449.
81. Rimm E.B., Stampfer M.J., Ascherio A. et al. Vitamin E consumption and the risk of coronary heart disease in men. New. Engl. J. Med. 328:1993;1450-1456.
82. Enstrom J.E., Kanim L.E., Klein M.A. Vitamin C intake and mortality among a sample of the US population. Epidemiology. 3:1993;194-202.
83. Hertog M.G.L., Feskens E.J.M., Hollman P.C.H., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease. The Zutphen Elderly Study. Lancet. 342:1993;1007-1011.
84. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. New. Engl. J. Med. 330:1994;1029-1035.
85. Omenn G.S., Goodman G.E., Thornquist M.D. et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. New. Engl. J. Med. 334:1996;1150-1155.
86. Hennekens C.H., Buring J.E., Manson J.E. et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. New. Engl. J. Med. 334:1996;1145-1149.
87. Rapola J.M., Virtamo J., Ripatti S. et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 349:1997;1715-1720.
88. Stephens N.G., Parsons A., Schofield P.M. et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
89. Singh R.B., Rastogi S.S., Verma R. et al. Randomised controlled trial of a cardioprotective diet in patients with a recent acute myocardial infarction: results of 1 year follow-up. Br. Med. J. 304:1992;1015-1019.
90. Huijbregts P., Feskens E., Räsänen L. et al. Dietary pattern and 20-year mortality in elderly men in Finland, Italy, and the Netherlands: longitudinal cohort study. Br. Med. J. 315:1997;13-17.
91. Trichopoulou A., Kouris-Blazos A., Wahlqvist M.L. et al. Diet and overall survival in elderly people. Br. Med. J. 311:1995;1457-1460.
92. Arch. Intern. Med. 153:1993;154-183.
93. INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 h urinary sodium and potassium excretion. Br. Med. J. 297:1988;319-328.
94. Appel L.J., Moore T.J., Obarzanek E. et al. A clinical trial of the effects of dietary patterns on blood pressure. New. Engl. J. Med. 336:1997;1117-1124.
95. Björntorp P. Obesity. Lancet. 350:1997;423-426.
96. Prevention and management of the global epidemic of obesity. Report of the WHO consultation on obesity (Geneva, June 3-5, 1997). Geneva: World Health Organization, 1998.
97. Seidell J.C. Dietary fat and obesity: an epidemiologic perspective. Am. J. Clin. Nutr. (Suppl). 67:1998;546-550.
98. Pate R.R., Blair S.N., Haskell W.L. et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. J. Am. Med. Assoc. 273:1995;402-407.
99. Bartechi C.E., MacKenzie T.D., Schrier R.W. The human costs of tobacco use (first of two parts). New. Engl. J. Med. 330:1994;907-912.
100. MacKenzie T.D., Bartechi C.E., Schrier R.W. The human costs of tobacco use (second of two parts). New. Engl. J. Med. 330:1994;975-980.
101. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am. Heart. J. 115:1988;242-249.
102. Manson J.E., Tosteson H., Ridker P.M. et al. The primary prevention of myocardial infarction. New. Engl. J. Med. 326:1992;1406-1416.
103. Prescott E., Hippe M., Schnohr P., Hein H.O., Vestbo J. Smoking and the risk of myocardial infarction in women and men: longitudinal population study. Br. Med. J. 316:1998;1043-1047.
104. Kawachi J., Colditz G.A., Stampfer M.J. et al. Smoking cessation in relation to total mortality rates in women. Ann. Intern. Med. 119:1993;992-1000.
105. Dwyer J.H. Exposure to environmental tobacco smoke and coronary risk. Circulation. 96:1997;1403-1407.
106. Liam T.H., He Y. Passive smoking and coronary heart disease: a brief review. Clin. Exp. Pharmacol. Physiol. 24:1997;993-996.
107. Law M.R., Morris J.K., Wald N.J. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. Br. Med. J. 315:1997;973-982.
108. Keys A, editor. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
109. Yano K., Reed D.M., McGee D.L. Ten-year incidence of coronary heart disease in the Honolulu Heart Program: relationship to biological and lifestyle characteristics. Am. J. Epidemiol. 119:1984;653-666.
110. Hammond E.C., Garfinkel L. Coronary heart disease, stroke and aortic aneurysm: factors in the etiology. Arch. Environ. Health. 19:1969;167-182.
111. Poikolainen K. Alcohol and mortality: a review. J. Clin. Epidemiol. 48:1995;455-465.
112. Duffy J. Alcohol consumption and all-cause mortality. Int. J. Epidemiol. 24:1995;100-105.
113. Thun M.J., Peto R., Lopez A.D., Monaco J.H., Henley J., Heath C.W., Doll R. Alcohol consumption and mortality among middle-aged and elderly US adults. New. Engl. J. Med. 337:1997;1705-1714.
114. Doll R., Peto R., Hall E., Wheatley K., Gray R. Mortality in relation to consumption of alcohol; 13 years' observations on male British doctors. Br. Med. J. 309:1994;911-918.
115. Shaper A.G., Wannamethee G., Walker M. Alcohol and coronary heart disease: a perspective from the British Regional Heart Study. Int. J. Epidemiol. 23:1994;482-494.
116. Rimm E.B., Klatsky A., Grobbee D., Stampfer M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? Br. Med. J. 312:1996;731-736.
117. Hein H.O., Suadicani P., Gyntelberg F. Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow-up in the Copenhagen male study. Br. Med. J. 312:1996;736-741.
118. Keil U., Chambless L.E., Döring A., Filipiak B., Stieber J. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology. 8:1997;150-156.
119. Rehm J.T., Bondy S.J., Sempos C.T., Vuong C.V. Alcohol consumption and coronary heart disease morbidity and mortality. Am. J. Epidemiol. 146:1997;495-501.
120. Renaud S., Beswick A.D., Fehily A.M., Sharp D.S., Elwood P.C. Alcohol and platelet aggregation: the Caerphilly Prospective Heart Disease Study. Am. J. Clin. Nutr. 55:1992;1012-1017.
121. Hendricks H.F.J., Veenstra J., Velthuisnte Wierik E.J.M., Shaafsma J., Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br. Med. J. 308:1994;1003-1004.
122. Klatsky A.L. Alcohol, coronary heart disease, and hypertension. Ann. Rev. Med. 47:1996;149-160.
123. Report of a Joint Working Group of the Royal College of Physicians, Psychiatrists and General Practitioners. Alcohol and heart in perspective. London: Royal College of Physicians of London, 1995.
124. Suhonen O., Aromaa A., Reunanen A., Knekt T.P. Alcohol consumption and sudden coronary death in middle-aged Finnish men. Acta. Med. Scand. 221:1987;335-341.
125. Kauhanen J., Kaplan G.A., Goldberg D.E., Salonen J.T. Beer binging and mortality: results from the Kuopio Ischaemic Heart Disease Risk Factor Study, a prospective population based study. Br. Med. J. 315:1997;846-851.
126. Larsson B. Obesity and body fat distribution as predictors of coronary heart disease. Marmot M., Elliott P. Coronary heart disease epidemiology. From aetiology to public health. 1992;233-241 Oxford University Press, London.
127. Willett W.C., Manson J.E., Stampfer M.J. et al. Weight, weight change, and coronary heart disease in women - risk within the 'normal weight range'. J. Am. Med. Assoc. 273:1995;461-465.
128. Rimm E.B., Stampfer M.J., Giovannucci E. et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am. J. Epidemiol. 141:1995;1117-1127.
129. Spataro J.A., Dyer A.R., Stamler J., Shekelle R.B., Greenlund K., Garside D. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J. Clin. Epidemiol. 49:1996;849-857.
130. Jousilahti P., Tuomilehto J., Vartiainen E., Pekkanen J., Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in Eastern Finland. Circulation. 93:1996;1372-1379.
131. Shaper A.G., Wannamethee S.G., Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle-aged men. Br. Med. J. 314:1997;1311-1317.
132. Harris T.B., Launer L.J., Madans J., Feldman J.J. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. Br. Med. J. 314:1997;1791-1794.
133. Reaven G.M. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
134. Prineas R.J., Folsom A.R., Kaye S.A. Central adiposity and increased risk of coronary mortality in older women. Ann. Epidemiol. 3:1993;35-41.
135. Folsom A.R., Kaye S.A., Sellers T.A. et al. Body fat distribution and 5-year risk of death in older women. J. Am. Med. Assoc. 269:1993;483-487.
136. Sandvik L., Erikssen J., Thaulow E., Erikssen G., Mundal R., Rodahl K. Physical fitness as a predictor of mortality in healthy middle-aged Norwegian men. New. Engl. J. Med. 328:1993;553-557.
137. Paffenbarger R.S. Jr, Hyde R.T., Wing A.L., Lee I.-M., Jung D.L., Kampert J.B. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. New. Engl. J. Med. 328:1993;538-545.
138. Blair S.N. Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. J. Am. Med. Assoc. 73:1995;1093-1098.
139. Rosengren A., Wilhemsen L. Physical activity protects against coronary death and death from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. Ann. Epidemiol. 7:1997;69-75.
140. Folsom A.R., Arnett D.K., Hutchinson R.G., Liao F., Clegg L.X., Cooper L.S. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med. Sci. Sports. Exerc. 29:1997;901-909.
141. Wannamethee S.G., Shaper A.G., Walker M. Changes in physical activity mortality, and incidence of coronary heart disease in older men. Lancet. 351:1998;1603-1608.
142. Physical activity and health. A report of the surgeon general. US DHHS 1996.
143. Goldbourt U. Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years. World. Rev. Nutr. Diet. 82:1997;229-239.
144. Leon A.S., Myers M.T., Connett J. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all causes in the multiple risk factor intervention trial (MRFIT). Int. J. Sports. Med. (Suppl. 3). 18:1997;208-215.
145. Shaper A.G., Wannamethee G., Walker M. Physical activity hypertension and risk of heart attack in men without evidence of ischaemic heart disease. J. Human. Hypert. 8(I):1994;3-10.
146. Blair S.N., Kampert J.B., Kohl H.W. et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. J. Am. Med. Assoc. 276:1996;205-210.
147. Pate R.R., Pratt M., Blair S.N. et al. Physical activity and public health: a recommendation from the Centre for Disease Control and prevention and the American College of Sports Medicine. J. Am. Med. Assoc. 273:1995;402-407.
148. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac rehabilitation as secondary prevention. Clinical practice guidelines. DHHS Agency for Health Care Policy and Research, NHLBI, AHCPRR, 1995, publication no. 96-0673.
149. Mittleman M.A., Maclure M., Tofler G.H., Sherwood J.B., Goldberg R.Y., Muller J.E. Triggering of acute myocardial infarction by heavy physical exertion - protection against triggering by regular exertion. New. Engl. J. Med. 329:1993;1677-1683.
150. Willich S.N., Lewis M., Lovel H., Arnte H.-K., Schubert F., Schröder R. Physical exertion as trigger of acute myocardial infarction. New. Engl. J. Med. 329:1993;1684-1690.
151. Oldridge N.B., Guyatt G.H., Fischer M.E., Rimm A.A. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. J. Am. Med. Assoc. 260:1988;945-950.
152. O'Connor G.T., Buring J.E., Yusuf S., Goldhaber S.Z., Olmstead E.M. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. 80:1989;234-244.
153. Orth-Gomer J., Chesney M.A. Social stress/strain and heart disease in women. Desmond G.J., Wenger N.K. Women and heart disease. 1997;407-420 Biddles, Guildford, UK.
154. Barefoot J.C., Schroll M. Symptoms of depression, acute myocardial infarction and total mortality in a community sample. Circulation. 93(11):1996;1976-1980.
155. Anda R., Williamson D., Jones D., Macera C., Baker E., Glassman A. Depressed-affect hopelessness and the risk of ischemic heart disease in a cohort of US adults. Epidemiology. 4:1993;285-294.
156. Williams R.B., Haney T.L., Lee K.L., Kong Y.H., Blumenthal J.A., Whalen R.E. Type A behaviour, hostility, and coronary atherosclerosis. Psychosom. Med. 42(6):1980;539-549.
157. Barefoot J.C., Dahlstrom W.G., Williams R.B. Hostility, CHD incidence and total mortality: a 25-year follow-up study of 255 physicians. Psychosom. Med. 45:1983;59-63.
158. Frasure-Smith N., Lesperance F., Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 91:1995;999-1005.
159. Everson S.A., Kauhanen J., Kaplan G.A. et al. Hostility and increased risk of mortality and acute myocardial infarction. The mediating role of behavioural risk factors. Am. J. Epidemiol. 146:1997;142-152.
160. Brunner E., Smith G.D., Marmot M. et al. Childhood social circumstances and psychological and behavioural factors as determinants of plasma fibrinogen. Lancet. 347:1996;1008-1013.
161. Rosengren A., Wilhemsen L., Welin L., Tsipogiaanni A., Teger-Nilsson A.C., Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. Br. Med. J. 300:1990;634-638.
162. Carney R.M., Saunders R.D., Freedland K.E., Stein P., Rich M.W., Jaffe A.S. Association of depression with reduced heart rate variability in coronary artery disease. Am. J. Cardiol. 76:1995;562-564.
163. Krittayaphong R., Cascio W.E., Light K.C. et al. Heart rate variability in patients with coronary artery disease. Differences in patients with higher and lower depression scores. Psychosom. Med. 59:1997;231-235.
164. McCraty R., Atkinson M., Tiller W.A., Rein G., Watkins A.D. The effects of emotions on short-term power spectrum analysis of heart rate variability. Am. J. Cardiol. 76:1995;1089-1093.
165. Mittleman A.M., Maclure M., Nachmani M. et al. Educational attainment, anger and the risk of triggering myocardial infarction onset. Arch. Intern. Med. 157:1997;769-775.
166. Oldenburg B., Graham-Clarke P., Shaw J., Walker S. Modification of health behavior and lifestyle mediated by physicians. Orth-Gomer K., Schneiderman N. Behavioral medicine approaches to crdiovascular disease prevention. 1996;203-226 Lawrence Arlbaum, Mahwah, NJ.
167. Ornish D., Brown S.E., Scherwitz L.W. et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 336(87708):1990;129-133.
168. Burell G. Behavioral medicine interventions in secondary prevention of coronary heart disease. Orth-Gomer K., Schnneiderman N. Behavioural medicine approaches to cardiovascular disease prevention. 1996;227-236 Lawrence Arlbaum, Mahwah, NJ.
169. McMahon R., Peto R., Cuttler J. et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;765-774.
170. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. J. Am. Med. Assoc. 275:1996;1571-1576.
171. Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart. J. 116:1988;1713-1724.
172. Walker W.G., Neaton J.D., Cutler J.A., Neuwirth R., Cohen J.D. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. J. Am. Med. Assoc. 268:1992;3085-3091.
173. Stamler R., Stamler Y., Grimm R. et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial. The Hypertension Control Program. J. Am. Med. Assoc. 257:1987;1484-1491.
174. Stamler R., Stamler Y., Gosch F.C. et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized controlled trial. J. Am. Med. Assoc. 262:1989;1801-1807.
175. Hypertension Prevention Trial: 3-year effects of dietary changes on blood pressure. Arch. Intern. Med. 150:1990;153-162.
176. Jula A., Rönnemaa T., Rastas M., Karvetti R.-L., Mäki Y. Long-term non-pharmacological treatment for mild to moderate hypertension. J. Intern. Med. 227:1990;413-421.
177. Langford H.G., Davis B., Oberman A. et al. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. Hypertension. 17:1991;210-217.
178. Wassertheil-Smoller S., Blaufox M.D., Oberman A.S., Langford H.G., Davis B.R., Wylie-Rosett Y. The trial of Antihypertensive Interventions and Management (TAIM) Study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch. Intern. Med. 152:1992;131-136.
179. Chalmers J., Morgan T., Doyle A. et al. Australian National Health and Medical Research Council Dietary Salt Study in Mild Hypertension. J. Hypertens. (Suppl. 6). 4:1986;629-637.
180. The effects of non-pharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention. Phase I. J. Am. Med. Assoc. 267:1992;1213-1220.
181. Grimm R.H. Jr, Grandits G.A., Cutler J.A. et al. Relationship of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch. Intern. Med. 157:1997;638-648.
182. Psaty B.M., Smith N.L., Siscovick D.S. et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. J. Am. Med. Assoc. 277:1997;739-745.
183. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 335:1990;827-838.
184. MacMahon S., Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence of 1994. Vasc. Med. Biol. 4:1994;265-271.
185. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol. 27:1996;1214-1218.
186. Mancia G., Grassi G. Considerations on current and future trials in hypertension. Blood. Pressure. 5:1996;327-332.
187. Kannel W.B., Gordon T. Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull. NY. Acad. Med. 54:1978;573-591.
188. Curb J.D., Maxwell M.H., Schneider K.A., Taylor J.O., Shulman N.B. Adverse effects of antihypertensive medications in the Hypertension Detection and Follow-up Program. Prog. Cardiovasc. Dis. (Suppl. 1). 29:1986;73-88.
189. Lindholm L., Ejlertsson G., Schersten B. High risks of cerebrocardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta. Med. Scand. 216:1984;251-259.
190. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood. Pressure. 1:1992;205-211.
191. Sytkowski P.A., D'Agostino R.B., Berlanger A.J., Kannel W.B. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. The Framingham Heart Study 1950-1990. Circulation. 93:1996;697-703.
192. Dahlöf B., Lindholm L.G., Hansson L., Schersten B., Ekbom T., Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
193. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 304:1992;405-412.
194. Amery A., Birkenhäger W., Brixko P. et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1:1985;1349-1354.
195. Coope J., Warrender T.S. Randomized trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. 293:1986;1145-1151.
196. Thijs L., Fagard R., Lijnen P., Staessen Y., Van Hoof R., Amery A. A meta-analysis of outcome trials in elderly hypertensives. J. Hypertens. 10:1992;1103-1109.
197. Staessen J., Amery A., Fagard R. Isolated stystolic hypertension in the elderly. J. Hypertens. 8:1990;393-405.
198. Kannel W.B., Dawber T.R., McGee D.L. Perspectives on systolic hypertension. the Framingham Study. Circulation. 61:1980;1179-1182.
199. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Med. Assoc. 265:1991;3255-3264.
200. Staessen J.A., Fagard R., Thijs L. et al. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 360:1997;757-764.
201. D'Agostino R.B., Belanger A.Y., Kannel W.B., Cruickshank J.M. Relationship of low diastolic blood pressure to coronary heart disease in the presence of myocardial infarction: the Framingham study. Br. Med. J. 303:1991;385-389.
202. Browner W.S., Hulley S.B. Effect of risk factor status on treatment criteria. Implications of hypertension trials. Hypertension. (Suppl. 1). 13:1989;51-56.
203. Flack J.M. Jr, Neaton J., Grimm R. et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 92:1995;2437-2445.
204. Cruickshank J.M. Blockers: primary and secondary prevention. J. Cardiovasc. Pharmacol. (Suppl). 11:1992;55-69.
205. Secondary prevention with verapamil after myocardial infarction. Am. J. Cardiol. 66:1990;331-401.
206. Protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. ISIS-4 Collaborative Group. Am. J. Cardiol. 68:1991;87D-100D.
207. Polese A., De Cesare N., Montorsi P. et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 83:1991;845-853.
208. Neaton J.D., Blackburn H., Jacobs D. et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch. Intern. Med. 152:1992;1490-1500.
209. Davey-Smith G., Shipley M.J., Marmot M.G., Rose G. Plasma cholesterol and mortality: the Whitehall Study. J. Am. Med. Assoc. 267:1992;70-76.
210. Chen Z., Peto R., Collins R., MacMahon S., Lu J., Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. Br. Med. J. 303:1991;276-282.
211. Ulvenstam G., Bergstrand R., Johansson S. et al. Prognostic importance of cholesterol levels after myocardial infarction. Prev. Med. 13:1984;355-366.
212. Pekkanen J., Linn S., Heiss J. et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. New. Engl. J. Med. 322:1990;1700-1707.
213. Wong N.D., Wilson P.W.F., Kannel W.B. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann. Intern. Med. 115:1991;687-693.
214. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
215. Pedersen T.R., Olsson A.G., Færgeman O. et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
216. Rosengren A., Hagman M., Wedel H., Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Eur. Heart. J. 18:1997;754-761.
217. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19 (Suppl A):A2-A11.
218. Abbot R.D., Wilson P.W., Kannel W.B., Castelli W.P. High density lipoprotein, total cholesterol screening and myocardial infarction. The Framingham Study. Arteriosclerosis. 8:1988;207-211.
219. Pocock S.J., Shaper A.G., Phillips A.N. HDL-cholesterol, triglycerides and total cholesterol in ischaemic heart disease. Br. Med. J. 298:1989;998-1002.
220. Manninen V., Huttunen J.K., Heinonen O.P., Tenkanen L., Frick M.H. Relationships between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am. J. Cardiol. 63:1989;42H-47H.
221. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Arch. Intern. Med. 152:1992;56-64.
222. Strategies for the prevention of coronary heart disease. Eur. Heart. J. 8:1987;77-88.
223. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992;2:113-56. Published also as a book - London: Current Medical Literature, 1993.
224. A desk top guide to the management of risk factors for coronary heart disease. European Atherosclerosis Society, 1992.
225. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
226. Austin M.A. Plasma triglycerides as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am. J. Epidemiol. 129:1989;249-259.
227. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 77:1996;1179-1184.
228. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Circulation. 97:1998;1029-1036.
229. Nordestgaard B.G. The vascular endothelial barrier - selective retention of lipoproteins. Curr. Opin. Lipidol. 7:1996;269-273.
230. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. III. Genetic analysis of lipid levels in 176 families and delineation of a new, inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52:1973;1544-1568.
231. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
232. Austin M.A. Triacylglycerol and coronary heart disease. Proc. Nutr. Soc. 56:1997;667-670.
233. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 96:1997;2520-2525.
234. Ericsson C.-G., Nilsson J., Svane B., Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20-50% diameter narrowing (Bezafibrate Coronary Atherosclerosis Intervention Trial, BECAIT). Am. J. Cardiol. 80:1997;1125-1129.
235. Haffner S.M., Applebaum-Bowden D., Wahl P.W. et al. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II and D, and lecithin cholesterol acyltransferase E: effect of smoking, alcohol and adiposity. Arteriosclerosis. 5:1985;169-177.
236. Robinson D., Ferns J.A., Bevan E.A., Stock J., Williams P.T., Galton D.J. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis. 7:1987;341-346.
237. Manninen V., Tenkanen H., Koskinen P. et al. Joint effects of serum triglycerides and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Disease Study. Implications for treatment. Circulation. 85:1992;37-45.
238. Manninen V., Elo M.O., Frick M.H. et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J. Am. Med. Assoc. 260:1988;641-651.
239. Frick M.H., Syvanne M., Nieminen M.S. et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 96:1997;2137-2143.
240. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerosis coronary artery disease (the PROCAM experience). Am. J. Cardiol. 70:1992;733-737.
241. Sniderman A.D., Shapiro S., Marpole D.G., Skinner B.F., Teng B., Kwiterovich P.O. Jr Association of coronary atherosclerosis with hyperbetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low-density (B) lipoproteins. PNAS. 77:1980;604-608.
242. Sandholzer C., Saha N., Kark J.D. et al. Apo(A) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler. Thromb. 12:1992;1214-1226.
243. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br. Med. J. 308:1994;367-373.
244. Fager G., Wiklung O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler. Thromb. Vasc. Biol. 17:1997;3527-3533.
245. Davey Smith G., Song F., Sheldon T.A. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br. Med. J. 306:1993;1367-1373.
246. Superko H.R., Krauss R.M. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 90:1994;1056-1069.
247. Waters D., Higginson L., Gladstone P. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
248. Sacks F.M., Pasternak R.C., Gibson C.M., Rosner B., Stone P.H. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 344:1994;1182-1186.
249. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet. 344:1994;633-638.
250. Pitt B., Mancini G.B.J., Ellis S.G., Osman H.S., Park J.-S., McGovern M.E. Pravastatin limitation of atheroslcerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. JACC. 26:1995;1133-1139.
251. Jukema J.W., Bruschke A.V.G., van Boven A.J. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
252. Herd J.A., Ballantyne C.M., Farmer J.A. et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study, LCAS). Am. J. Cardiol. 80:1997;278-286.
253. Tamura A., Mikuriya Y., Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Am. J. Cardiol. 79:1997;893-896.
254. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery by-pass grafts. New. Engl. J. Med. 336:1997;153-162.
255. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 2:1984;600-604.
256. Jacobs D., Blackburn H., Higgins M. et al. Report of the Consensus on Low Blood Cholesterol: mortality associations. Circulation. 86:1992;1046-1060.
257. Lewis B., Tikkanen M.J. Blood total cholesterol and mortality: causality, consequence and confounders. Am. J. Cardiol. 73:1994;80-85.
258. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs. Br. Med. J. 304:1992;431-434.
259. Pedersen T.R., Berg K., Cook T.J. et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 156:1996;2085-2092.
260. Miettinen T.A., Pyörälä K., Olsson A.G. et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 96:1997;4211-4218.
261. Crouse III J.R., Byington R.P., Hoen H.M., Furberg C.D. Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med. 157:1997;1305-1310.
262. Herbert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J. Am. Med. Assoc. 278:1997;313-321.
263. Caro J., Klittich W., McGuire A. et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br. Med. J. 315:1997;1577-1582.
264. Jönsson B., Johannesson M., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H. Cost-effectiveness of cholesterol lowering. Eur. Heart. J. 17:1996;1001-1007.
265. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am. J. Cardiol. 79:1997;756-762.
266. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes. Care. 20:1997;614-620.
267. Goldbourt U., Behar S., Reicher-Reis H. et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (Bezafibrate Infarction Prevention Trial). Am. J. Cardiol. 71:1993;909-915.
268. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. New. Engl. J. Med. 317:1987;1237-1245.
269. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes. Metab. Rev. 3:1987;463-524.
270. Krolewski A.S., Kosinski E.J., Warram J.H. et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol. 59:1987;750-755.
271. Yudkin J.S., Blauth C., Drury P. et al. Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. Diabet. Med. (Suppl). 13:1996;101-121.
272. Laakso M., Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes. Rev. 5:1997;294-315.
273. Haffner S.M., Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am. J. Med. 103:1997;152-162.
274. Nathan D.M., Meigs J., Singer D.E. The epidemiology of cardiovascular disease in Type 2 diabetes mellitus: how sweet it is... or is it? Lancet. (Suppl. I). 350:1997;4-9.
275. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes. Care. 21:1998;160-178.
276. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes. Care. 20:1997;1183-1197.
277. Alberti K.G.M.M., Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and clarification of diabetes mellitus. Provisional Report of a WHO Consultantion. Diabet. Med. 15:1998;539-553.
278. Diabetes mellitus. Report of a WHO Study Group. Technical Report Series 646. Geneva: World Health Organization, 1985.
279. Balkau B., Shipley M., Jarrett R.J. et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes. Care. 21:1998;360-367.
280. Klein R. Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes. Care. 18:1995;258-268.
281. Kuusisto J., Mykkänen L., Pyörälä K., Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 43:1994;960-967.
282. Lehto S., Rönnemaa T., Haffner S.M., Pyörälä K., Kallio V., Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 46:1997;1354-1359.
283. Turner R.C., Millns H., Neil H.A.W. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UK prospective diabetes study (UKPDS:23). Br. Med. J. 316:1998;823-828.
284. The effect of intensive treatment of diabetics on the development and progress of the long-term complications in insulin dependent diabetes mellitus. New. Engl. J. Med. 329:1993;977-986.
285. Turner R.C., Holman R.R. The UK Prospective Diabetes Study. Ann. Med. 28:1996;439-444.
286. Malmberg K., Rydén L., Efendic S. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J. Am. Coll. Cardiol. 26:1995;57-65.
287. Nesto R.W., Zarich S. Acute myocardial infarction in diabetes mellitus. Lessons learned from ACE inhibition. Circulation. 97:1998;12-15.
288. Manson J.E., Golditz G.A., Stampfer M.J. et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch. Intern. Med. 151:1991;1141-1147.
289. Stamler J., Vaccaro O., Neaton J., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes. Care. 14:1991;173-194.
290. Adlerbert A.M., Rosengren A., Wilhelmsen L. Diabetes and long-term risk of mortality from coronary heart disease and other causes in middle-aged Swedish men. A general population study. Diabetes. Care. 21:1998;539-545.
291. A strategy for arterial risk assessment and management in Type 2 (non-insulin-dependent) diabetes mellitus. Diabet. Med. 14:1997;611-621.
292. Fuller JH, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy in diabetes mellitus. Cochrane Rev (updated 28/08/1997).
293. Curb J.D., Pressel S.L., Cutler J.A. et al. Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J. Am. Med. Assoc. 276:1996;1886-1892.
294. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomised Trial. Lancet. 351:1998;1755-1762.
295. Mykkänen L., Rönnemaa T., Marniemi J., Haffner S.M., Bergman R., Laakso M. Insulin sensitivity is not an important determinant of plasminogen activator inhibitor-1 activity. Arterioscler. Thromb. 14:1994;1264-1271.
296. Juhan-Vague I., Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78:1997;656-660.
297. Laakso M. Insulin resistance and coronary heart disease. Curr. Opin. Lipidol. 7:1996;217-226.
298. Boushey C., Beresford S.A.A., Omenn G., Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1995;1049-1057.
299. Alfthan G., Pekkanen J., Jauhianen M. et al. Relations of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
300. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocysteine and risk of cardiovascular disease in Multiple Risk Factor Interventional Trial. Arterioscler. Thromb. Vasc. Biol. 17:1997;1947-1953.
301. Graham I.M., Daly L.E., Refsum H.M. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J. Am. Med. Assoc. 277:1997;1775-1781.
302. Harmon DL, Woodside JV, Yarnell JWG, et al. The common 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med 1996;89-571-7.182.
303. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9,179.
304. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin J. Fibrinogen as a risk factor for stroke and myocardial infarction. New. Engl. J. Med. 311:1984;501-505.
305. Mead T.W., Mellows S., Brozovic M. et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. II:1986;533-537.
306. Kannel W.B., Wolf P.A., Castelli W.P., D'Agostino R.B. Fibrinogen and risk of cardiovascular disease. J. Am. Med. Assoc. 258:1987;1183-1186.
307. Yarnell J.W.G., Baker I.A., Sweetman P.M. et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart diseases: the Caerphilly and Speewell Collaborative Heart Disease Studies. Circulation. 83:1991;836-844.
308. Bara L., Nicaud V., Tiret L., Cambien F., Samama M.M. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIc and PAI-1 in European offspring: the EARS Study. Thromb. Haemost. 71:1994;434-440.
309. Behague I., Poirier O., Nicaud V. et al. Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation. 93:1996;440-449.
310. Meade T.W. Fibrinogen and other clotting factors in cardiovascular disease. Francis R.B. Jr Atherosclerotic vascular disease, hemostasis, and endothelial function. 1992;1-32 Marcel Dekker, New York.
311. Junker R., Heinrich J., Schulte H., van de Loo J., Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler. Thromb. Vasc. Biol. 17:1997;1539-1544.
312. Folsom A.R., Wu K.K., Shahar E., Davis C.E. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler. Thromb. 13:1993;1829-1836.
313. Hamsten A., Wiman B., De Faire U., Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New. Engl. J. Med. 313:1985;1557-1563.
314. Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. II:1987;3-9.
315. Eriksson P., Kallin B., Van't Hooft F.M., Bavenholm P., Hamsten A. Allele specific increase in basal transcription of the PAI-1 gene is assocaited with myocardial infarction. Proc. Natl. Acad. Sci. USA. 92:1995;1851-1855.
316. Ye S., Green F.R., Scarabin P.Y. et al. The 4G/5G genetic polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb. Haemost. 74:1995;837-841.
317. Thaulow E., Erikssen J., Sandvik K.-L. et al. Blood platelet count and function are related to total and cardiovascular health in apparently healthy men. Circulation. 84:1991;613-617.
318. Elwood P.C., Renaud S., Sharp D.S., Beswick A.D., O'Brien J.R., Yarnell J.W. Ischaemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation. 83:1991;38-44.
319. Wu K.K. Genetic markers: genes involved in thrombosis. JCR. 4:1997;347-352.
320. Weiss E.J., Bray P.F., Tayback M. et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New. Engl. J. Med. 334:1996;1090-1094.
321. Walter D.H., Schachinger V., Elsner M., Dimmeler S., Zether A.M. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 350:1997;1217-1219.
322. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:1994;81-106.
323. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 351:1998;233-241.
324. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:1997;461-466.
325. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144:1996;537-547.
326. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New. Engl. J. Med. 336:1997;973-979.
327. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL-cholesterol in determining risk of first myocardial infarction. Circulation. 97:1998;2007-2011.
328. Koenig W., Froehlich M., Sund M. et al. C-reactive protein (CRP) predicts the risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augsburg cohort study, 1984/85-1992. Circualtion. (Suppl. I). 96:1997;1-99. (Abstract).
329. Tracy R., Lomalue R., Psaty B. et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler. Thromb. Vasc. Biol. 17:1997;1121-1127.
330. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:1998;425-428.
331. Mendall M.A., Patel P., Asante M. et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 78:1997;273-277.
332. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J. Am. Med. Assoc. 279:1998;1477-1482.
333. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.K., Allen J. Plasma concentrations of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92.
334. Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 350:1997;430-436.
335. Muhlestein J.B., Hammond E.H., Carlquist J.F. et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27:1996;1555-1561.
336. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
337. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. Randomized trial of roxithromycin in non Q wave coronary syndromes: ROXIS pilot study. Lancet. 350:1997;404-407.
338. Inman W.H.W., Vessey M.F., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br. Med. J. 2:1970;203-209.
339. Mann J.J. Oral contraceptives and the cardiovascular risk. Oliver M.F. Coronary heart disease in young women. 1978;184-194 Churchill Livingstone, Edinburgh.
340. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. WHO Technical Report Series 877. Geneva: World Health Organization, 1998.
341. Oliver M.F., Boyd J.S. Effect of bilateral ovariectomy on coronary artery disease and serum lipid levels. Lancet. II:1959;690-694.
342. Robinson R.W., Higano N., Cohen W.D. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch. Intern. Med. 104:1959;908-913.
343. Palmer J.R., Rosenberg L., Shapiro S. Reproductive factors and risk of myocardial infarction. Am. J. Epidemiol. 136:1992;408-416.
344. Bush T.L., Barrett-Connor E., Cowan L.D. et al. Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinic's Program Follow-up Study. Circulation. 75:1987;1002-1009.
345. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease:a quantitative assessment of the epidemiologic evidence. Prev. Med. 26:1991;47-63.
346. Grady D., Rubin S.H., Petitti D.B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117:1992;1016-1037.
347. Wallentin L., Larsson-Cohn V. Metabolic and hormonal effects of postmenopausal oestrogen replacement treatment. II. Plasma lipids. Acta. Endocrinol. 86:1977;597-607.
348. Wanl P., Walden C., Knoop R. et al. Effect of oestrogen/progestin potency on lipid/lipoprotein cholesterol. New. Engl. J. Med. 308:1983;862-867.
349. Cauley J.A., La Parte R., Kuller L. et al. Menopausal oestrogen use, high density cholesterol subfractions and liver function. Atherosclerosis. 49:1983;31-39.
350. Barrett-Connor E., Slone S., Greendale G. et al. The Post-menopausal Estrogen/Projestin Intervention Study: primary outcomes in adherent women. Maturitas. 27:1997;261-274.
351. Brinton L.A. The relationship of exogenous oestrogens to cancer risk. Cancer. Detect. Prev. 7:1984;159-171.
352. Shapiro S., Kelly J., Rosenberg L. et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. New. Engl. J. Med. 313:1955;969-972.
353. Brinton L.A., Hoover R., Fraumeni J.F. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br. J. Cancer. 54:1986;825-832.
354. Wingo P.A., Layde P.M., Lee N.C. et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. J. Am. Med. Assoc. 257:1987;209-215.
355. Bergkvist L., Adami H.O., Persson J. et al. The risk of breast cancer after oestrogen and oestrogen-progestin replacement. New. Engl. J. Med. 321:1989;193-197.
356. Marenberg M.E., Risch N., Berkman L.F., Floderus B., De Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New. Engl. J. Med. 330:1994;1041-1046.
357. Wilson P.W.F., Schaefer E.J., Larson M.G., Ordovas J.M. Apo E allele and risk of coronary disease a meta-analysis. Atheroscler. Thromb. Vasc. Biol. 16:1996;1250-1255.
358. Cambien F., Evans A.E. The angiotensin-I converting enzyme (ACE) gene polymorphism and coronary heart disease. Eur. Heart. J. (Suppl. K). 16:1995;13-22.
359. Montgomery H.E., Clarkson P., Dollery C.M. et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 96:1997;741-747.
360. Amant C., Bauters C., Bodart J.C. et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 96:1997;56-60.
361. Ribichini F., Steffenino G., Dallavalle A. et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme a major risk factor and a marker of risk of coronary stent restenosis. Circulation. 97:1998;147-154.
362. Pinto Y.M., van Gilst W.H., Kingma H., Schunkert H. Deletion-allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. J. Am. Coll. Cardiol. 25:1995;1622-1626.
363. Andersson B., Sylven C. The DD genotype of the angiotensin converting enzyme gene is associated with increased mortality in idiopathic heart failure. J. Am. Coll. Cardiol. 28:1996;162-167.
364. Montgomery H.E., Clarkson P., Nwose O.M. et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G453A polymorphism of the β-fibrinogen gene. Arterioscler. Thromb. Vasc. Biol. 16:1996;386-391.
365. Gardemann A., Schwartz O., Haberbosch W. et al. Positive association of the β-fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb. Haemost. 77:1997;1120-1126.
366. De Maat M.P.M., Kastelein J.J.P., Jukema J.W. et al. 455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Arterioscler. Thromb. Vasc. Biol. 18:1998;265-271.
367. Fumeron F., Betoulle D., Luc G. et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J. Clin. Invest. 96:1995;1664-1671.
368. Jacques P.F., Bostom A.G., Williams R.R. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
369. Harmon D.L., Woodside J.V., Yarnell J.W.G. et al. The common thermolabile variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q. J. Med. 89:1996;571-577.
370. Cusi D., Barlassina C., Azzani T. et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet. 349:1997;1353-1357.
371. Wilhelmsen L. Salt and hypertension. Clin. Sci. 57:1979;455S-458S.
372. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO technical report series 854. Geneva: World Health Organization, 1995.
373. Han T.S., van Leer E.M., Seidell J.C., Lean M.E.J. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br. Med. J. 311:1995;1401-1415.
374. Mancia G., Ferrari A.U., Gregorini L. et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ. Res. 53:1983;96-104.
375. The Australian Therapeutic Trial in Mild Hypertension. Lancet. 1:1980;1261-1267.
376. Mancia G., Di Rienzo M., Parati G. Ambulatory blood pressure monitoring: use in hypertension research and clinical practice. Hypertension. 21:1993;510-524.
377. Pickering T.G., James G.D., Boddie C., Harsfield G.A., Blank S., Laragh J.H. How common is white coat hypertension? J. Am. Med. Assoc. 259:1988;225-228.
378. Mancia G., Bertinieri G., Parati G. et al. Effects of blood pressure measurement by the doctor on patients' blood pressure and heart rate. Lancet. 2:1983;695-698.
379. Mancia G., Parati G., Pomidossi G., Grassi G., Casadei R., Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 9:1987;209-215.
380. Mancia G., Sega R., Bravic C., De Vito G., Valagussa F., Cesana G., Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA study. J. Hypert. 13:1995;1377-1390.
381. Staessen J., Fagard R., Lijnen P., Thijs L., Van Hoof R., Amery A. Mean and range of ambulatory blood pressure in normotensive subjects from a meta-analysis of 23 studies. Am. J. Cardiol. 67:1991;723-727.
382. Mancia G., Zanchetti A. Editor's corner: white-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J. Hypertens. 14:1996;1049-1052.
383. McCall M., Elmfeldt D., Vedin A., Wilhelmsson C., Wedel H., Wilhemsen L. Influence of myocardial infarction on blood pressure and serum cholesterol. Acta. Med. Scand. 206:1979;477-481.
384. Yu H.H., Ginsburg G.S., Harris N., Rifai N. Evaluation and clinical application of a direct low-density lipoprotein cholesterol assay in normolipidemic and hyperlidemic adults. Am. J. Cardiol. 80:1997;1295-1299.
385. Mbewn A.D., Durrington P.N., Bulleid S., Mackness M.I. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apo A1 and B lipids and C-reactive protein. Atherosclerosis. 103:1993;65-71.
386. Shankat N., Ashraf S.S., Mackness M.I., Mbewn A.D., Bhatnagar D., Durrington P.N. A prospective study of serum lipoproteins after coronary bypass surgery. Q. J. Med. 87:1994;539-545.
387. Guidelines for cardiac exercise testing. Eur. Heart. J. 14:1993;969-988.
388. Prochaska J.O., DiClemente C.C., Norcross J.C. In search of how people change: Applications to addictive behavior. Am. Psychol. 47:1992;1102-1114.
389. Prochaska J.O., Vilicer W.F., DiClemente C.C., Fava J. Measuring processes of change: a pplication to the cessation of smoking. J. Cons. Clin. Psychol. 56:1988;520-525.
390. Kottke T.E., Battista R.N., De Friese G.H., Brekke M.L. Attributes of successful smoking cessation interventions in medcial practice: a meta-analysis of 39 controlled trials. J. Am. Med. Assoc. 259:1988;2883-2889.
391. Law M., Tang J.L. An analysiss of effectiveness of interventions intended to help people stop smoking. Arch. Int. Med. 155:1995;1933-1941.
392. Schwartz J. Review and evaluation of smoking cessation methods: the US and Canada 1978-1985. National Institute of Health Publication 87-2940. Washington, DC: US Government Printing Office, 1987.
393. Austoker J., Sanders D., Fowler G. Smoking and cancer: smoking cessation. Br. Med. J. 308:1994;1478-1482.
394. Ockene I.S., Houston Miller N. Cigarette smoking, cardiovascular disease, and stroke. Circulation. 96:1997;3243-3247.
395. Silagy C., Mant D., Fowler G., Lodge M. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation. Lancet. 343:1994;139-142.
396. Joseph A.M., Norman S.M., Ferry L.H. et al. The safety of transdermal nicotine as an aid to smoking cessation in ptients with cardiac disease. New. Engl. J. Med. 335:1996;1792-1798.
397. Long-term comprehensive care of cardiac patients. Eur. Heart. J. (Suppl. C). 13:1992;1-45.
398. Fletcher G.F. How to implement physical activity in primary and secondary prevention. Circulation. 96:1997;355-357.
399. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. J. Hypertens. 11:1993;905-918.
400. Arch. Intern. Med. 157:1997;2413-2445.
401. Hypertension control. Report of a WHO Expert Committee. WHO Technical Report Series 862. Geneva: World Health Organization, 1996.
402. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of ecocardiographically determined left ventricular mass in the Framingham Heart Study. New. Engl. J. Med. 322:1990;1561-1566.
403. Casale P.N., Devereaux R.B., Milner M. Value of ecocardiographic left ventricular mass in protecting cardiovascular morbid events in hypertensive men. Ann. Int. Med. 105:1986;173-178.
404. Devereaux R.B. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. Laragh J.H., Brenner B.M. Hypertension: pathophysiology. Diagnosis and management. 1990;359-377 Raven Press, New York, NY.
405. Deckert T., Koford-Enevoldsen A., Norgaard K., Borch-Johnsen K., Feldt-Rassmudsen B., Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes. Care. 15:1992;1181-1191.
406. Yudkin J.S., Forrest R.D., Jackson C.A. Microalbuminuria as a predictor of cardiovascular disease in non-diabetic subjects. The Islington Diabetes Survey. Lancet. II:1988;530-533.
407. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New. Engl. J. Med. 329:1993;1456-1462.
408. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New. Engl. J. Med. 334:1996;939-945.
409. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann. Intern. Med. 127:1997;337-345.
410. Bakris G.L., Mangrum A., Copley J.B., Vicknair N., Sadler R. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 29:1997;744-750.
411. Groppelli A., Giorgi D.M.A., Omboni S., Parati G., Mancia G. Persistent blood pressure increase induced by heavy smoking. J. Hypert. 10:1992;495-499.
412. Furberg C.D., Psaty B.M., Cuttler G.A. Blood pressure and cardiovascular disease. Yusuf S., Cairns J.A., Camm A.J., Fallen E.L., Gersch B.J. Evidence based cardiology. 1998;226-238 BMJ Books, London.
413. Mancia G., Grassi G. Combination treatment in antihypertensive drug trials (editorial). Cardiovasc. Drug. Ther. 11:1997;517-518.
414. Isles C.G., Walker L.M., Beevers G.D. et al. Mortality in patients of the Glasgow blood pressure clinic. J. Hypertens. 4:1986;141-156.
415. Gong L., Zhang W., Zhu Y. et al. Shangai Trial of Nifedipine in the Elderly (STONE). J. Hypertens. 14:1996;1237-1245.
416. Hansson L. The Captopril Prevention Project (CAPP): description and status. Am. J. Hypertens. 7:1994;82S-83S.
417. Cruickshank J.M., Thorp J.M., Zacharias F.J. Benefits and potential harm of lowering high blood pressure. Lancet. 1:1987;581-583.
418. D'Agostino R.B., Belanger A.Y., Kannel W.B., Cruickshank J.M. Relationship of low diastolic blood pressure to coronary heart disease in the presence of myocardial infarction. Br. Med. J. 303:1991;385-389.
419. Mancia G., Sega R., Milesi C., Cesana G., Zanchetti A. Blood-pressure control in the hypertensive populaton. Lancet. 349:1997;454-457.
420. Sacks F.M., Moyé L.A., Davis B.R. et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation. 97:1998;1446-1452.
421. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
422. Triglyceride, high-density lipoprotein, and coronary heart disease. J. Am. Med. Assoc. 269:1993;505-510.
423. Gould A.L., Rossouw J.E., Santanello N.C. et al. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation. 91:1995;2274-2282.
424. Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes. Res. Clin. Pract. 28:1995;103-117.
425. European Policy Group 1998. A desk-top guide to Type 1 (insulin-dependent) diabetes mellitus. Europe: International Diabetes Federation, 1998.
426. European Policy Group 1998. A desk-top guide to Type 2 (non-insulin-dependent) diabetes mellitus. Europe: International Diabetes Federation, 1998.
427. Standards of medical care for patients with diabetes mellitus. Diabetes. Care. (Suppl. 1). 21:1998;23-31.
428. Hennekens C.H., Dyken M.L., Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for Healthcare Professionals from the American Heart Association. Circulation. 96:1997;2751-2753.
429. Yusuf S., Peto R., Lewis J., Collins R., Fleight P. Blockade during and after myocardial infarction, an overview of the randomised trials. Prog. Cardiovasc. Dis. 27:1984;335-371.
430. Yusuf S., Held P., Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in the light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am. J. Cardiol. 67:1991;1295-1297.
431. Latini R., Maggioni A., Flather M., Slight P., Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 92:1995;3132-3137.
432. Effect of enalapril on survival in patients with reduced left ventricular election fractions and congestive heart failure. New. Engl. J. Med. 325:1991;293-302.
433. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular election fractions. New. Engl. J. Med. 327:1992;685-691.
434. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. New. Eng. J. Med. 327:1992;669-677.
435. Cohn J.N., Johnson G., Zlesche S. et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. New. Engl. J. Med. 325:1992;303-310.
436. Fonarow G.C., Chatimsky-Fallick C., Warnes Stevenson L. et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure, the Hy-C Trial. J. Am. Coll. Cardiol. 19:1992;842-850.
437. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
438. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 343:1994;1115-1122.
439. Ambrosini E., Borghi C., Magani B. Survival of myocardial infarction. Long-term Evaluation (SMILE) Study: rationale, design, organisation and outcome definitions. Controlled. Clin. Trials. 15:1994;201-210.
440. A randomzied factorial trial assessing early oral captopril, mononitrate and intravenous magnesium sulphate in over 58050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infant Survival) Collaborative Group. Lancet. 345:1995;66-85.
441. Smith P., Arneson H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New. Engl. J. Med. 323:1990;147-152.
442. Needs and Priorities in Cardiac Rehabilitation and Secondary Prevention in Patients with Coronary Heart Disease. WHO Technical Report Series 831. Geneva: WHO, 1993.
443. Cardiac rehabilitation programs. A statement for healthcare professionals. Circulation. 90:1994;1602-1610.
444. Guidelines for cardiac rehabilitation. 2nd ed:1995;Human Kenetics Books, Champaign, Illnois.
445. Gohlke H., Gohlke-Barwolf C. Cardiac rehabilitation. Eur. Heart. J. 19:1998;1004-1010.
446. Pearson TA, Peters TD, Feury D. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study: attainment of goals for comprehensive risk reduction in patients with coronary heart disease in the US. J Am Coll Cardiol 1998;31 (SupplA):186A (Abstract).
447. Pearson T.A., Peters T.D. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am. J. Cardiol. 80:1997;45H-52H.
448. Prochaska J.O., DiClemente C.C., Norcross J.C. In search of how people change: applications to addictive behavior. Am. Psychol. 47:1992;1102-1114.
449. Debusk R.F., Miller N.H., Superko R. et al. A case-management system for coronary risk factor modification after myocardial infarction. Ann. Intern. Med. 120:1994;721-729.
450. Bandura A. The exercise of control. 1997;Freeman, New York.
451. Fullard E., Weston S., Schofield T., Moher M. Managing established coronary heart disease. Br. Med. J. 315:1997;69-70.
452. Prochaska J.O., Vilicer W.F., DiClemente C.C., Fava J. Measuring processes of change: application to the cessation of smoking. J. Cons. Clin. Psychol. 56:1988;520-525.
453. Kolonel L.N., Lee J. Husband-wife correspondence in smoking, drinking and dietary habits. Am. J. Clin. Nutrition. 34:1981;99-104.
454. Sackett D.L., Anderson G.D., Milner R., Feinleib M., Kannel W.B. Concordance for coronary risk factors among spouses. Circulation. 52:1975;589-595.
455. Garrison R.J., Castelli W.P., Feinleib M. et al. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am. J. Epidemiol. 110:1979;313-321.
456. McGee H.M., Graham T., Newton H., Morgan J.H. The involvement of the spouse in cardiac rehabilitation. Ir. J. Psychol. 15:1994;203-218.
457. Pyke S.D.M., Wood D.A., Kinmonth A.L., Thompson S.G. Changes in coronary risk factor levels in couples following lifestyle intervention: the British Family Heart Study. Arch. Fam. Med. 6:1997;3254-3260.
458. Houston Miller N., Hill M., Kottke T., Ockeme I.S. The Multilevel Compliance Challenge: recommendations for a call to action. A statement for Health Care Professionals. AHA scientific report. Circulation. 95:1997;1085-1090.
459. Wexler L., Brundage B., Crouse I. et al. Coronary artery calcification in pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for Health Professionals from the American Heart Association. Circulation. 94:1996;1175-1192.
460. Solberg L.A., Strong J.P. Risk factors for atherosclerotic lesions: a review of autopsy studies. Atherosclerosis. 3:1983;187-198.
461. Criqui M.H., Langer R.D., Fronek A. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. New. Engl. J. Med. 326:1992;381-386.
462. Leng G.C., Fowkes F.G., Lee A.J., Dunbar J., Housley E., Ruckley C.V. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br. Med. J. 313:1996;1440-1444.
463. Salonen R., Tervahauta M., Dalonen J.T., Pekkanen J., Nissinen A., Karvonen M.J. Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern Finnish men. Prevalence and assocaitions with cardiovascular diseases and risk factors. Arterioscler. Thromb. 14:1994;1631-1640.
464. Burke G.L., Evans G.W., Riley W.A. et al. Arterial wall thickness is assocaited with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 26:1995;386-391.
465. O'Leary D.H., Polak J.F., Kronmal R.A. et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascualr Health Study Collaborative Research Group. Stroke. 27:1996;224-231.
466. Wofford J.L., Kahl F.R., Howard G.R., McKinney W.M., Toole J.F., Crouse III J.R. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler. Thromb. 11:1991;786-794.
467. Adams M.R., Nagakomi A., Keech A. et al. Carotid intima media-thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 92:1995;2127-2134.
468. Hulthe J., Wikstrand J., emanuelsson H., Wiklund O., de Feyter P.J., Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke. 28:1997;1189-1194.
469. De Groot E., Jukema J.W., Montauban van Swijndregt A.D. et al. B-Mode ultraosund assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol. 31:1998;1561-1567.
470. Salonen J.T., Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler. Thromb. 11:1991;1245-1249.
471. Chambless L.E., Heiss G., Folsom A.R. et al. Association of coroanry heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 146:1997;483-494.
472. Furberg C.D., Adans H.P. Jr, Applegate W.B. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 90:1994;1679-1687.
473. Crouse III J.R., Byington R.P., Bond M.G. et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 75:1995;455-459.
474. Salonen R., Nyyssönen K., Porkkala E. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 92:1995;1758-1764.
475. MacMahon S., Sharpe N., Gamble G. et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. Lipid Trial Research Group. Circulation. 97:1998;1784-1790.
476. The International Task Force for Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk. The scientific background to primary and secondary prevention. A worldwide view. Nutr Metab Cardiovasc Dis 1998; 8 (in press).